Hepatitis C treatment and SVR: The gap between clinical trials and real-world treatment aspirations

General Hospital Psychiatry

Volumn 35, Issue 2, 2013, Pages 122-128

  North, Carol S ^a,b,c   Hong, Barry A ^d   Adewuyi, Sunday A ^b   Pollio, David E ^e   Jain, Mamta K ^c   Devereaux, Robert ^b   Quartey, Nana A ^f   Ashitey, Sarah ^g   Lee, William M ^b   Lisker Melman, Mauricio ^d  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHN PETER SMITH HOSPITAL   (United States)

Author keywords

Course of treatment; HCV HIV coinfection; Hepatitis C; Psychosocial barriers to treatment; Sustained virologic response

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG RESEARCH; DRUG RESPONSE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL DISEASE; MIXED INFECTION; PATIENT SELECTION; SUSTAINED VIROLOGIC RESPONSE;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COINFECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 84875367462     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.11.002     Document Type: Article

References (39)

1. Adeyemi O.M., Jensen D., Attar B., et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS 2004, 18:239-245.
2. Andersen R.M. Revisiting the behavioral model and access to medical care: does it matter?. J Health Soc Behav 1995, 36:1-10.
3. Bini E.J., Brau N., Currie S., et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005, 100:1772-1779.
4. Booth C.M. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past. Clin Cancer Res 2010, 16:5963-5971.
5. Butt A.A., Wagener M., Shakil A.O., et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005, 12:81-85.
6. Cacoub P., Halfon P., Rosenthal E., et al. Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: modifications in three consecutive large surveys between 2004 and 2009. J Hepatol 2010, 53:230-237.
7. Cacoub P., Halfon P., Rosenthal E., et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol 2008, 48:35-42.
8. Cacoub P., Rosenthal E., Halfon P., et al. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat 2006, 13:678-682.
9. Cawthorne C.H., Rudat K.R., Burton M.S., et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002, 97:149-155.
10. Delwaide J., El Saouda R., Gerard C., et al. Hepatitis C infection: eligibility for antiviral therapies. Eur J Gastroenterol Hepatol 2005, 17:1185-1189.
11. Doab A., Treloar C., Dore G.J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005, 40(Suppl 5):S313-S320.
12. Falck-Ytter Y., Kale H., Mullen K.D., et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288-292.
13. Fleming C.A., Craven D.E., Thornton D., et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003, 36:97-100.
14. Fleming C.A., Tumilty S., Murray J.E., et al. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 2005, 40(Suppl 5):S349-S354.
15. Goldberg R.W. Supported medical care: a multi-faceted approach to helping HIV/hepatitis C virus co-infected adults with serious mental illness. AIDS 2005, 19(Suppl 3):S215-S220.
16. Grebely J., Genoway K.A., Raffa J.D., et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008, 93:141-147.
17. Groom H., Dieperink E., Nelson D.B., et al. Outcomes of a hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol 2008, 42:97-106.
18. Hall C.S., Charlebois E.D., Hahn J.A., et al. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004, 19:357-365.
19. Lindenburg C.E., Lambers F.A., Urbanus A.T., et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011, 23:23-31.
20. Mallet V., Vallet-Pichard A., Pol S. New trends in hepatitis C management. Presse Med 2010, 39:446-451.
21. McLaren M., Garber G., Cooper C. Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can J Gastroenterol 2008, 22:133-137.
22. McNally S., Temple-Smith M., Sievert W., et al. Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Public Health 2006, 30:422-427.
23. Mehta S.H., Genberg B.L., Astemborski J., et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008, 33:126-133.
24. Mehta S.H., Thomas D.L., Sulkowski M.S., et al. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS 2005, 19(Suppl 3):S179-S189.
25. Moirand R., Bilodeau M., Brissette S., et al. Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage. Can J Gastroenterol 2007, 21:355-361.
26. Morrill J.A., Shrestha M., Grant R.W. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005, 20:754-758.
27. Muir A.J., Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002, 34:268-271.
28. Murray M.C., Barrios R., Zhang W., et al. Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. Eur J Gastroenterol Hepatol 2011, 23:45-50.
29. Nunes D., Saitz R., Libman H., et al. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res 2006, 30:1520-1526.
30. Rowan P.J., Tabasi S., Abdul-Latif M., et al. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004, 38:530-534.
31. Scheft H., Fontenette D.C. Psychiatric barriers to readiness for treatment for hepatitis C virus (HCV) infection among injection drug users: clinical experience of an addiction psychiatrist in the HIV-HCV coinfection clinic of a public health hospital. Clin Infect Dis 2005, 40(Suppl 5):S292-S296.
32. Seal K.H., Currie S.L., Shen H., et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter?. J Clin Gastroenterol 2007, 41:199-205.
33. Shatin D., Schech S.D., Patel K., et al. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care 2004, 10:250-256.
34. Sylvestre D.L., Clements B.J. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007, 19:741-747.
35. Sylvestre D.L., Litwin A.H., Clements B.J., et al. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005, 29:159-165.
36. Sylvestre D.L., Zweben J.E. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007, 18:406-410.
37. Thompson V.V., Ragland K.E., Hall C.S., et al. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS 2005, 19(Suppl 3):S208-S214.
38. Volk M.L., Tocco R., Saini S., et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50:1750-1755.
39. Zickmund S., Hillis S.L., Barnett M.J., et al. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 2004, 39:999-1007.